Dishman Carbogen Amcis Ltd.
NSE: DCAL · Healthcare
Sector
Healthcare
Size band
Small cap
Market cap
2,356cr
ROE
-0.2%
No price is shown on this page, live or delayed. It records what management said on the earnings call, and the company’s filings.
Measured against
Peer set
Pharmaceuticals & Drugs · largest 12 of 82 measured at Q1 FY27 · financials via Screener| Company | Operating margin | Revenue growth |
|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 29.0% | 10.5% |
| Divi's Laboratories Ltd. | 41.0% | 27.8% |
| Torrent Pharmaceuticals Ltd. | 34.0% | 54.8% |
| Lupin Ltd. | 30.0% | 32.1% |
| Dr. Reddy's Laboratories Ltd. | 11.0% | −5.5% |
| Cipla Ltd. | 17.0% | 2.3% |
| Zydus Lifesciences Ltd. | 24.0% | 22.0% |
| Mankind Pharma Ltd. | 26.0% | 12.9% |
| Aurobindo Pharma Ltd. | 21.0% | 16.3% |
| Torrent Power Ltd. | 19.0% | 2.8% |
| Alkem Laboratories Ltd. | 20.0% | 10.9% |
| Dishman Carbogen Amcis Ltd. | 9.0% | −4.2% |
What management said
11 statements on recordEarnings call · First Quarter Ending June 30, 2026 / Q1 FY27 · 21 Aug 2026
- Revenue growth→single-digit growth· FY27
“We do expect single-digit growth as far as the revenues are concerned.”
- EBITDA margin→similar to what we did last year; maybe a little bit higher· FY27
“As far as the EBITDA margin is concerned, it should be similar to what we did last year. Maybe it could be a little bit higher, but that's more or less the guidance.”
- Revenue growth→more than 10% growth in the revenue YoY· FY28-FY29
“All of this should help us to achieve more than 10% growth in the revenue YoY.”
- EBITDA margin→closer to the 25-26%· FY28-FY29
“The EBITDA margin should be closer to the 25-26% that we were doing prior to the EDQM issues that we had at the India sites.”
- Debt refinancing / promoter fund infusion→up to CHF 200 million· multiple tranches
“the total amount for which we have taken the approval is up to CHF 200 million. I mean, not that the entire CHF 200 million would come in one tranche, but it would be in multiple tranches.”
- Debt refinancing interest cost and tenor→4% all-inclusive; 10 years
“The interest cost is going to be at 4% all-inclusive, and the overall tenor that we are looking at is 10 years.”
- Net debt→somewhere around CHF 140-150 million· FY27 and FY28
“Well, from a net debt perspective, I think we should be somewhere around CHF 140-150 million and this is in Swiss franc, and that would be the right way to look at our debt.”
- Net debt reduction→roughly about CHF 8-9 million· FY27 and FY28
“we expect that the net debt should reduce by roughly about CHF 8-9 million.”
- Interest expense→roughly about INR 130-140 crores· full year
“Roughly about INR 130-140 crores.”
- India entity revenue growth→at least 30-35%· current financial year
“The Indian entity, as such, for the current financial year, the revenue should increase by at least 30-35% as compared to the previous year.”
- India entity operating margin→close to about 10%· current financial year
“As far as the margins are concerned, at an operating level, we should be at close to about 10%.”
Taken from management commentary on the company’s earnings call and quoted verbatim. These are statements of intent made by the company, not forecasts by Bharatstox, and nothing here records whether they were met.
No broadcast calls recorded.
We log calls made about a company on business television — Zee Business, CNBC Awaaz and NDTV Profit — as they are stated on air. Nothing is on record for Dishman Carbogen Amcis Ltd..
Shareholding
change across 4 filings| Category | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Change |
|---|---|---|---|---|---|
| Promoters | 59.3 | 59.3 | 59.3 | 59.3 | 0.0 |
| Foreign institutions | 6.9 | 7.5 | 7.7 | 8.1 | −1.2 |
| Domestic institutions | 2.1 | 1.6 | 1.3 | 1.4 | +0.7 |
| Retail & others | 31.8 | 31.6 | 31.8 | 31.2 | +0.6 |
As filed with the exchange for the periods ending Sep 25 to Jun 26.
Filings
latest 25 of 222- Allotment of Securities15 Oct 2026
- Certificate under SEBI (Depositories and Participants) Regulations, 20188 Oct 2026
- Outcome of Board Meeting7 Oct 2026
- Shareholders meeting1 Oct 2026
- Shareholders meeting30 Sept 2026
- Shareholders meeting30 Sept 2026
- Allotment of Securities28 Sept 2026
- Trading Window24 Sept 2026
- Please find attached herewith Newspaper Advertisement for AGM and E-Voting Instructions.7 Sept 2026
- Copy of Newspaper Publication7 Sept 2026
- Copy of Newspaper Publication2 Sept 2026
- Please find attached herewith Newspaper Advertisement for an intimation regarding the 19th AGM to be held through VC or OAVM.2 Sept 2026
- Updates31 Aug 2026
- Please find attached herewith an Intimation regarding date of AGM to be held on 30/09/2026.31 Aug 2026
- Analysts/Institutional Investor Meet/Con. Call Updates21 Aug 2026
- Please find enclosed herewith transcript of conference call held on 17th August, 2026.21 Aug 2026
- Analysts/Institutional Investor Meet/Con. Call Updates17 Aug 2026
- Allotment of Securities17 Aug 2026
- Investor Presentation17 Aug 2026
- Outcome of Board Meeting14 Aug 2026
- Analysts/Institutional Investor Meet/Con. Call Updates12 Aug 2026
- Analysts/Institutional Investor Meet/Con. Call Updates12 Aug 2026
- Outcome of Board Meeting12 Aug 2026
- Copy of Newspaper Publication17 Jul 2026
- Certificate under SEBI (Depositories and Participants) Regulations, 201814 Jul 2026
The 25 most recent of 222 filings we hold for DCAL, back to January 2024. Every filing, by day.
Disclaimer
Guidance is quoted from management commentary on quarterly earnings calls; the words are the company's own and the targets are theirs, not ours. Peer comparisons use quarterly financials sourced from Screener, with every company measured at the same fiscal quarter; the peer set is companies sharing the same industry classification, and comparisons are descriptive, not a ranking or a view. Filings are reproduced as companies filed them to the NSE and BSE; Bharatstox does not verify, endorse or comment on their contents. This page is for informational and educational purposes only and does not constitute investment advice, research, or a recommendation to buy or sell any security. Investing in securities markets is subject to market risks. Read all related documents carefully before investing.